Media About Us


  • 29 June 2017

    Syndax Locks In To Tumor Escape

    Syndax Locks In To Tumor Escape

    Seeking Alpha

    Syndax (NASDAQ:SNDX) is a $315 million market cap company focused on developing a pipeline of innovative combination therapies for cancer. The company's lead product is Entinostat, which was granted Breakthrough Therapy Designation by FDA for its Phase 2b clinical trial in advanced hormone receptor positive (Estrogen Receptor positive, ER+) breast cancer. The impact of Breakthrough Therapy Designation on biotechnology stocks has been previously described here by Strong Bio and is worth a read. The company has a host of impressive partnerships for its clinical trials, including Merck (NYSE:MRK) for a combinatory non-small cell lung cancer (NSCLC) and melanoma therapy, Genentech/Roche (OTCQX:RHHBY) for triple-negative breast cancer (TNBC), and Pfizer (NYSE:PFE) and Merck in Germany for ovarian cancer.

  • 16 June 2017

    LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

    LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

    LA BioMed

    The Medical Mycology Society of the Americas has honored John E. “Jack” Edwards, Jr., MD, an LA BioMed lead researcher, as the winner of the 2017 Rhoda Benham Award. The award is given “to an individual from the Americas for continuous outstanding or meritorious contributions to medical mycology,” which is the study of fungal diseases. Dr. Edwards, together with his group of colleagues, founded NovaDigm Therapeutics to translate the three decades of research into products that will prevent or treat serious infectious diseases. 

  • 15 June 2017

    OD reports practices success with corneal inlay

    OD reports practices success with corneal inlay

    Jeffrey M. Augustine, OD / Healio

    The keys to success with the Raindrop Near Vision Inlay are patient selection and evaluation of ocular surface, centration and inflammation, he said. The use of corneal inlays for the surgical correction of presbyopia is an exciting new technology for optometry, ophthalmology and, especially, for the presbyopic patient.

  • 05 June 2017

    The three factors crucial to effectiveness in healthcare

    The three factors crucial to effectiveness in healthcare

    SPIEF-2017. Panel discussion "The three factors crucial to effectiveness in healthcare". “The problem and task is to boost the system’s performance within the budget available for now. That does not mean the system needs no more money, that means spending must be efficient,” said Leonid Melamed, Chairman of the Board of Directors, Team Drive.

  • 01 June 2017

    Plant to produce Pfizer sterile injectables for Russia gets under way

    Plant to produce Pfizer sterile injectables for Russia gets under way

    Eric Palmer / Fierce Pharma

    Russia's NovaMedica is building a new sterile injectables plant in the Kaluga region where it will produce 30 of Pfizer’s sterile injected generic meds for the local market.

  • 01 June 2017

    Construction of a new pharmaceutical plant started in Vorsino Industrial Park

    Construction of a new pharmaceutical plant started in Vorsino Industrial Park

    GMP News

    On May 30, Vorsino Industrial Park in the Kaluga region hosted an official ceremony to mark the start of construction of an advanced biopharmaceutical production facility owned by NovaMedica LLC (a RUSNANO investment project).

  • 17 May 2017

    Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle

    John Carroll / Endpoints News

    Briggs Morrison has good reason today to be glad he left the Big Pharma R&D world behind at AstraZeneca and switched to biotech. The CEO of Waltham, MA-based Syndax reported that the company’s lead drug in combination with Merck’s Keytruda cleared its first big hurdle in Phase II and will now transition into the second phase of the study.

  • 16 May 2017

    Forever Young: 10 Anti-Aging Startups To Watch

    Forever Young: 10 Anti-Aging Startups To Watch

    CB Insights Blog

    By 2050, the US population aged 65 and older is projected to reach 83.7M, almost double its population in 2012. To combat the aging process and help people lead longer and healthier lives, pharmaceutical corporates and tech giants alike have begun investing in startups that are specifically aiming to tackle the root causes of aging or age-related diseases. One of them - ReVision Optics.

  • 02 May 2017

    Epic Sciences nets $40M for cancer liquid biopsy

    Epic Sciences nets $40M for cancer liquid biopsy

    Amirah Al Idrus / FierceBiotech

    Epic Sciences raised $40 million in a Series D round, which it will use to ramp up clinical studies of its liquid biopsy tests that identify cancer patients who will benefit from specific treatments.

  • 02 May 2017

    Biopharma just cant get enough of Epic Sciences

    Biopharma just cant get enough of Epic Sciences

    Juliet Preston / MedCityNews

    Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.